BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 18, 2026
Home » Topics » Medical technology

Medical technology
Medical technology RSS Feed RSS

Ekos completes SEATTLE II trial for treatment of PE

March 21, 2013

People in the News

March 21, 2013

Keeping you up to date on recent developments in orthopedics

March 21, 2013

DePuy offers an up-close 'experience' of Attune knee

March 21, 2013
CHICAGO — Day two of the American Academy of Orthopedic Surgeons (AAOS; Rosemont, Illinois) 2013 annual meeting kicked off inside McCormick Place with the official opening of the technology exhibits on the main floor. Occupying space among the many exhibitors is the DePuy Synthes Joint Reconstruction Division of DePuy Orthopedics (Warsaw, Indiana). Among the technology products from DePuy is its latest innovation in total knee replacement, the Attune knee system.
Read More

Optical sensing technique could lend itself to healthcare industry

March 21, 2013
By Omar Ford

Huge potential markets await Actium if new technology is okayed

March 21, 2013
By Jim Stommen

Washington roundup: FDA: Everest II trial data not enough to approve MitraClip

March 21, 2013
By Mark McCarty

Financings roundup: Cardiovascular Systems looking to raise $33 million in offering

March 21, 2013

A refreshing take on the state of the med-tech industry

March 20, 2013
By Amanda Pedersen
Charles Dickens at his desk in 1858. Dickens' famous opening line from "A Tale of Two Cities" could easily be applied to the current state of the medical device industry, "It was the best of times, it was the worst of times." Here at Medical Device Daily we've become accustomed to the doom-and-gloom stories about our industry. The medical device tax provision in the Affordable Care Act and other emerging realities of healthcare reform along with worldwide economic sluggishness, regulatory and reimbursement challenges, consolidation among hospitals and an increase in hospital-employed physicians has created the perfect storm for the medical device industry....
Read More

HIT roundup: Health eShare initiative unveiled in Tennessee

March 20, 2013
Previous 1 2 … 3594 3595 3596 3597 3598 3599 3600 3601 3602 … 10247 10248 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Illustration of tau accumulating in a neuron cell.

    Biogen AD drug shows tau, cognition benefit, despite trial miss

    BioWorld
    Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing